شركة Aurora Cannabis Inc. (ACB): تحليل مصفوفة ANSOFF

في صناعة القنب سريعة التطور، تقف شركة أورورا كانابيس (ACB) عند مفترق طرق حاسم في التحول الاستراتيجي. من خلال التنقل في المشهد المعقد لتوسيع السوق، وابتكار المنتجات، والتنويع الاستراتيجي، تستعد الشركة للاستفادة من نهجها الفريد وفق مصفوفة أنسوف لإعادة تعريف موقعها التنافسي. من القنوات المباشرة للمستهلك إلى الأبحاث الطبية الرائدة، لا تكتفي أورورا كانابيس بالتكيف مع السوق—بل تعمل بنشاط على إعادة تشكيل مستقبل ابتكار القنب والتفاعل مع المستهلكين.

شركة أورورا كانابيس (ACB) - مصفوفة أنسوف: اختراق السوق

توسيع قنوات المبيعات المباشرة للمستهلك من خلال المنصات الإلكترونية

في الربع الثالث من عام 2022، أعلنت أورورا كانابيس عن صافي إيرادات بلغت 62.1 مليون دولار كندي، حيث شكلت المبيعات عبر الإنترنت حوالي 15% من إجمالي الإيرادات. وشهدت المنصة الرقمية للشركة زيادة بنسبة 22% في عدد المستخدمين المسجلين مقارنة بالربع السابق.

زيادة جهود التسويق الموجهة لمستخدمي الحشيش الطبي والترفيهي

خصصت شركة أورورا كانابيس 8.7 مليون دولار كندي لنفقات التسويق في السنة المالية 2022، مستهدفة أسواق الحشيش الطبي والترفيهي على حد سواء.

• قطاع سوق الحشيش الطبي: 35% من ميزانية التسويق
• قطاع سوق الحشيش الترفيهي: 65% من ميزانية التسويق

تحسين استراتيجيات التسعير لجذب المستهلكين الحساسين للسعر

انخفض متوسط سعر الغرام الواحد من منتجات أورورا كانابيس من 7.23 دولار كندي في الربع الثاني من 2022 إلى 6.85 دولار كندي في الربع الثالث من 2022، ما يعكس استراتيجية تسعير تنافسية.

تعزيز برامج ولاء العلامة التجارية للاحتفاظ بالقاعدة العملاء الحالية

قامت شركة أورورا كانابيس بتنفيذ برنامج ولاء يضم 78,000 عضو مسجل، محققة معدل احتفاظ بالعملاء يبلغ 62% في السنة المالية 2022.

تحسين جودة المنتج والاتساق لتعزيز موقع السوق

استثمرت الشركة 12.5 مليون دولار كندي في مراقبة الجودة والبحث والتطوير في عام 2022، مما أدى إلى تحقيق معدل اتساق بالمنتجات بنسبة 95% عبر خطوط منتجات القنب الخاصة بها.

شركة أورورا كانابيس (ACB) - مصفوفة أنسوف: تطوير السوق

استكشاف الأسواق الدولية للقنب

قامت أورورا كانابيس بالتوسع إلى الأسواق الدولية من خلال عمليات في:

توسيع شبكات التوزيع في المقاطعات الكندية

توسيع شبكة التوزيع عبر المقاطعات الكندية:

• ألبرتا: حصة السوق 24.5%
• أونتاريو: حصة السوق 20.3%
• كولومبيا البريطانية: حصة السوق 15.7%

استهداف شرائح عملاء جديدة

تطوير شراكات استراتيجية

شراكات بحثية مع:

• مركز البحوث الطبية بجامعة تورنتو
• مركز ماكجيل الصحي
• جامعة كولومبيا البريطانية

إبرام اتفاقيات ترخيص

شركة أورورا كانابيس (ACB) - مصفوفة أنسوف: تطوير المنتجات

الاستثمار في البحث والتطوير لمنتجات طبية مبتكرة مشتقة من القنب

في السنة المالية 2022، استثمرت شركة أورورا كانابيس 31.7 مليون دولار كندي في نفقات البحث والتطوير. وقد قدمت الشركة 9 طلبات براءات اختراع تتعلق بصيغ القنب والعلاجات الطبية.

إنشاء خطوط منتجات متخصصة تستهدف حالات طبية محددة

طورت شركة أورورا 7 خطوط منتجات طبية متخصصة بالقنب تستهدف حالات مثل:

• إدارة الألم المزمن
• الاضطرابات العصبية
• تخفيف أعراض تتعلق بالسرطان
• علاجات الصحة النفسية

تطوير صيغ متقدمة للقنب بملفات كانابينويد فريدة

أنتجت أورورا كانابيس 12 صيغة كانابينويد فريدة بنسب THC:CBD محددة تتراوح من 1:1 إلى 20:1.

تقديم منتجات العناية ونمط الحياة المدمجة بالقنب

أطلقت شركة أورورا 5 خطوط منتجات للعناية، محققة إيرادات بلغت 14.2 مليون دولار كندي من منتجات القنب غير الطبية في عام 2022.

توسيع نطاق المنتجات بعلاجات قنب قياسية ومطابقة للمستوى الدوائي

قامت الشركة بتطوير 3 علاجات قنب بمستوى دوائي تتوافق مع معايير الصحة الكندية الصارمة. إجمالي الاستثمار في تطوير المنتجات ذات المستوى الدوائي: 22.5 مليون دولار كندي.

شركة أورورا كانابيس (ACB) - مصفوفة أنسوف: التنويع

الاندماج الرأسي في زراعة القنب ومعالجته وبيعه بالتجزئة

استثمرت شركة أورورا كانابيس مبلغ 122 مليون دولار كندي في مرافق الإنتاج عبر عدة مقاطعات كندية. وحتى عام 2021، كانت الشركة تدير 11 مرفق إنتاج بقدرة إنتاجية سنوية إجمالية تبلغ 75,000 كجم من القنب.

الاستثمار في منتجات المستهلك المعتمدة على القنب

خصصت أورورا 5.2 مليون دولار أمريكي لتطوير المنتجات المستخلصة من القنب في عام 2020. تشمل فئات المنتجات:

• مكملات الصحة المحتوية على CBD
• منتجات العناية بالبشرة الموضعية
• مواد غذائية مستخلصة من القنب

منصات أبحاث وتكنولوجيا القنب

بلغ الاستثمار في البحث والتطوير 18.3 مليون دولار كندي في عام 2020، مع التركيز على تقنيات أبحاث القنب الملكية.

الاستثمارات الاستراتيجية في التكنولوجيا الحيوية

التزمت شركة أوروورا بمبلغ 12.7 مليون دولار أمريكي لشراكات التكنولوجيا الحيوية في مجال القنب في 2020-2021.

توسيع السوق المرتبط بالقنب

بلغت استثمارات توسيع السوق 22.5 مليون دولار كندي في قطاعات تكنولوجيا العافية والمعدات المتخصصة.

• منصات تكنولوجيا العافية
• معدات زراعة القنب
• أنظمة مراقبة الصحة الرقمية

Aurora Cannabis Inc. (ACB) - Ansoff Matrix: Market Penetration

Market penetration for Aurora Cannabis Inc. is a clear, dual-pronged strategy: aggressively defend and expand the high-margin medical business while right-sizing the lower-margin consumer segment. You need to focus your capital on the areas delivering the biggest returns, and the numbers from fiscal year 2025 (FY2025) make that choice obvious.

The core of this strategy is leveraging the financial strength of the medical segment-which delivered 75% of Aurora's Q4 2025 consolidated net revenue-to increase market share in existing geographies. This isn't about new markets; it's about selling more of what you already have to the customers you already serve.

Increase Canadian medical market share by leveraging the 70% adjusted gross margin

The Canadian medical market is your cash cow. In Q4 2025, the adjusted gross margin (before fair value adjustments) on medical cannabis net revenue hit a stellar 70%, up from 66% in the prior year period. That's a margin profile that demands investment. Your Canadian medical net revenue for Q4 2025 was $26.8 million (CAD), and the goal here is to push that number higher by capturing competitor's patients.

Here's the quick math: keeping costs flat, every $1 million in new medical revenue brings in about $700,000 in adjusted gross profit. You need to allocate marketing and patient education spend directly against this high-margin opportunity. One clean one-liner: Protect the margin, grow the revenue.

Aggressively promote proprietary, high-THC flower like Sourdough and Farm Gas in existing Canadian markets

The premiumization of your product line is directly tied to that 70% margin. Your proprietary, next-generation cultivars, such as Sourdough and Farm Gas, are a competitive edge because they consistently deliver high-potency flower, often with THC levels in the high 20s and sometimes exceeding 30%. This is what the market demands, and it's where the high margins are generated.

Your action is to ensure these strains are always in stock and prominently featured in your Canadian medical channels. This isn't just about sales; it's about brand equity in the high-THC segment, which is a key driver for patient retention.

Optimize pricing and distribution for the consumer (adult-use) segment, which saw revenue drop to $8.2 million in Q4 2025

The consumer (adult-use) segment is a different beast entirely. In Q4 2025, consumer cannabis net revenue dropped to $8.2 million (CAD), a 20% decrease year-over-year. This decline was a deliberate strategic choice to prioritize high-margin medical sales, but you can't abandon the market. The good news is the consumer segment's adjusted gross margin improved to 27% in Q4 2025, up from 16% in the prior year, showing your portfolio optimization is working.

The strategy here is surgical: maintain profitability, not chase volume. Focus distribution on a smaller, higher-value product set. You need to be defintely smart about where you compete in the consumer space.

Deepen patient loyalty in Canada with the expanded compassionate pricing program

Loyalty is the cheapest form of market share. Your expansion of the compassionate pricing program in June 2025 is a smart move that builds goodwill and locks in repeat prescription volume. By raising the yearly income eligibility threshold from $40,000 to $60,000 CAD, you've made the program the most inclusive medical cannabis pricing plan in Canada.

The program offers a 30% discount on all cannabis products for eligible patients. This isn't just a discount; it's a barrier to switching brands. The action is to ensure every patient knows about the new $60,000 CAD threshold and the 30% savings, making Aurora the clear value leader for a massive segment of the population.

Target repeat prescription volume in core medical markets like Germany and Australia

International medical sales are your primary growth engine for market penetration. In Q4 2025, international net revenue was $41 million (CAD), representing a massive 61% of your global medical net revenue. This segment grew by 48% year-over-year, driven by strong sales in Germany and Australia.

However, you need to be a trend-aware realist: the market is getting competitive. Sales in Australia declined for a second consecutive quarter in Q2 FY2026, leading to a $13.2 million impairment charge on intangible assets and goodwill. The action is to double down on prescription volume in Germany, where you've secured leadership, and fight to stabilize Australia by aggressively promoting product availability and clinical education to prescribers. You must win the repeat business to justify your international investment.

Aurora Cannabis Inc. (ACB) - Ansoff Matrix: Market Development

Market Development, in the context of Aurora Cannabis Inc., means taking the company's existing, proven medical cannabis products and brands-like MedReleaf and Aurora-and introducing them to new, regulated geographical markets. This strategy is the core driver of the company's recent financial turnaround, moving away from volatile recreational markets toward high-margin, federally regulated medical exports.

The success of this approach is clear in the fiscal 2025 results: Aurora generated a record annual global medical cannabis net revenue of $244.4 million, marking a substantial 39% year-over-year growth. In the fourth quarter of fiscal 2025 alone, international revenue more than doubled, accounting for 61% of the total global medical cannabis net revenue. This proves the model works, so the next step is to expand the geographic footprint and deepen market penetration in emerging regions.

Expand EU-GMP certified medical exports beyond the core markets of Germany, Australia, Poland, and the UK.

The foundation of Aurora's international strategy is its adherence to European Union Good Manufacturing Practice (EU-GMP) standards, which is the pharmaceutical-grade benchmark for exporting medical cannabis to Europe and other global markets. The company solidified its supply chain in July 2025 by securing EU-GMP certification for its dedicated distribution center in Brampton, Ontario. This addition gives Aurora a total of four EU-GMP certified facilities in its global network, positioning it as the largest Canadian exporter of medical cannabis.

This increased capacity is vital for expanding beyond the four core markets-Germany, Australia, Poland, and the UK-which drove the Q4 2025 medical cannabis revenue growth. To be defintely successful, Aurora must now convert this supply chain advantage into market share in other European nations that are advancing their medical programs.

• Leverage the July 2025 EU-GMP distribution certification to increase total export volume to smaller, established markets like New Zealand.
• Prioritize new distribution agreements in countries with nascent medical programs, such as Spain, where regulations are slowly opening up.
• Use the German manufacturing facility, which is receiving a five-year investment for operational upgrades as of September 2025, as a hub to increase supply chain efficiency across the continent.

Enter new, regulated medical markets in Latin America or Asia with established MedReleaf and Aurora medical brands.

The next logical step is planting the flag in new continents. While Aurora already mentions operating in 'South America', formal entry into new, specific countries is the key market development action. The Latin American medical cannabis market is valued at approximately $2.6 billion in 2025, and the Asia-Pacific market is valued at $6.2 billion, representing significant untapped potential.

The strategy here is to use the established, high-quality reputation of the MedReleaf and Aurora medical brands, which are already trusted in core markets, to enter these new regulatory frameworks. This minimizes the product risk but requires navigating complex local regulations, a challenge Aurora has proven capable of handling in Germany and Australia.

Here's the quick math on the market opportunity:

Establish a strategic distribution network to capitalize on potential US federal cannabis rescheduling or state-level medical expansion.

The US market remains the ultimate prize, but federal prohibition complicates direct entry. Aurora's strategic move is a contingency plan: they hold warrants that give them the option to acquire a 40% ownership interest in Australis Capital (a US-focused entity) if federal law permits. This arrangement allows them to retain their NASDAQ and TSX listings while preparing for a major shift.

The trigger for this action is the pending federal rescheduling of cannabis from Schedule I to a less restrictive classification, such as Schedule III, which was still unresolved as of September 2025. Rescheduling would remove the crippling Section 280E tax burden on US cannabis companies, immediately boosting their profitability and valuation, and clearing the path for Canadian-listed companies to enter the market.

• Maintain the strategic warrants for Australis Capital, ensuring a rapid entry mechanism upon federal policy change.
• Monitor DEA and DOJ proceedings closely; the DOJ's court case challenging the rescheduling process is stayed until at least January 2026.
• Focus on high-margin medical products for a potential initial US entry, leveraging the existing MedReleaf and Aurora brands.

Launch the Whistler Cannabis Co. brand in additional international markets following the successful August 2025 debut in Australia.

The Whistler Cannabis Co. brand, known for its premium, indoor craft cannabis, represents a high-end product line that can command a premium price in international medical markets. Its August 12, 2025, launch in Australia, starting with high-potency cultivars like Ginger Breath (32% THC) and Critical Diesel (28% THC), was a clear market development move.

The next action is to take this successful playbook and apply it to other high-margin markets, particularly in Europe, where the premium segment often sees less competition. This diversifies the product portfolio beyond the core Aurora and MedReleaf offerings and targets the segment of patients willing to pay more for craft quality.

Secure new government tenders for medical cannabis supply in emerging European countries.

Securing a government tender (a formal contract to supply a national medical program) provides long-term revenue visibility and volume certainty. While Aurora has a history of winning tenders in Germany and Italy, the focus now must be on emerging tender-based markets to mitigate the risk of headwinds in existing countries, such as the slight decline in international revenue expected for Q1 2026 due to Poland.

The strategy is to proactively compete for new contracts in countries that are transitioning from pilot programs to full-scale national supply. This leverages the company's EU-GMP certification and proven track record of supplying pharmaceutical-grade cannabis to government agencies.

• Actively bid on new, large-volume tenders in markets like France, which is expected to move beyond its trial period, or Italy, for renewal or expansion of existing contracts.
• Leverage the $41 million in international medical cannabis net revenue from Q4 2025 as proof of reliable, large-scale supply capability.

Aurora Cannabis Inc. (ACB) - Ansoff Matrix: Product Development

The core of Aurora Cannabis Inc.'s Product Development strategy is to expand its high-margin medical and premium consumer offerings by introducing new formats and proprietary genetics into its existing markets. This focus is defintely paying off, as evidenced by the $67.8 million in medical cannabis net revenue reported for Q4 Fiscal Year 2025, a 48% increase year-over-year. The company is moving beyond basic flower and oils to target specific patient and consumer needs with advanced, high-potency, and discreet products.

Accelerate the rollout of innovative formats like the cannabis-infused ready-to-drink beverage across existing medical markets.

Aurora is using innovative delivery systems, like rapid-onset beverages, to capture the growing demand for alternatives to smoking and traditional edibles. The company's Versus brand offers products like the Black Cherry Rapid Seltzer and Blueberry Pomegranate Rapid Seltzer, each containing 8.5-11.5 mg of THC per serving. While initially a consumer product, accelerating the medical market rollout of these formats, particularly in international markets like Germany and Australia, is a clear opportunity. These new formats appeal to patients seeking precise, smoke-free dosing and quick effects, which is crucial for maintaining the 70% adjusted gross margin seen in the Q4 2025 medical segment.

Introduce high-potency chewable extracts (like Drift: Glitches) to capture the growing demand for discreet, high-dose formats.

The market for high-dose, discreet edibles is expanding, and Aurora is positioning itself with products like Drift: Glitches. This chewable extract is a first-of-its-kind, delivering a substantial 10mg THC per piece. This format is a direct response to consumer preference mapping that shows a clear demand for high-potency products. The Glitches product is available in flavors like Pomegranate Berry and Pineapple Coconut, offering a convenient, measured dose in packages of 5 x 10mg or 10 x 10mg. Honestly, this product line helps them compete directly against illicit market potency while retaining the quality control of a regulated product.

Commercialize minor cannabinoid (CBN) oils and other specialized extracts to address specific patient needs in the $67.8 million Q4 2025 medical segment.

The medical segment, which generated $67.8 million in Q4 2025, thrives on specialized products that target specific conditions, moving beyond just THC and CBD. Aurora is actively commercializing minor cannabinoids (CBN) to address issues like sleep and relaxation. The company's medical marketplace already features products like MediPharm Labs CBN 1:2 NightTime Formula and CBN:CBD 1:2 Relax Formula. This focus on a wider range of cannabinoids, including Cannabinol (CBN) and Cannabigerol (CBG), is a low-risk, high-return strategy because it leverages existing extraction infrastructure to tap into the growing wellness and nutraceutical trend within the medical space.

Launch new proprietary flower genetics, such as Electric Honeydew, to the Canadian adult-use market under existing brands like San Rafael '71.

Aurora's in-house genetics breeding program is a key competitive advantage. The launch of new proprietary cultivars, like Electric Honeydew, is vital for maintaining market share in the premium dried flower segment. Electric Honeydew is a high-THC hybrid, consistently testing between 24-30% THC. The company's fall product release also included other high-potency strains like Farm Gas (27% THC) and Sourdough (29% THC) for international medical markets like Poland. This strategy ensures a continuous pipeline of unique, high-quality flower that commands a premium price, which is essential given the Canadian consumer market's competitive pricing pressure.

Invest in R&D to develop next-generation vaporizers and delivery systems for existing medical oils and concentrates.

Product innovation isn't just about the cannabis itself; it's about the delivery. Aurora's R&D investment supports the development of advanced hardware to improve the patient experience, especially for medical oils and concentrates. For example, the AURORA 918 EHD-CA vape cartridge for Electric Honeydew extract utilizes a proprietary ACTIVE 510 thread cartridge with a ceramic mouthpiece, designed for optimal delivery of the 765 mg/g THC oil. Here's the quick math: with R&D expenses running at about $1.0 million in Q1 2025, a portion of this capital is directly allocated to improving these systems, which reduces patient complaints and increases product loyalty.

• Develop next-generation 510 thread cartridges to minimize clogging and improve vapor quality.
• Focus R&D on precision dosing mechanisms for medical oils to enhance patient safety and efficacy.
• Commercialize 31 new SKUs in markets like Australia and New Zealand during Fiscal Year 2025, spanning vapes, concentrates, and oils.

Finance: Track the revenue contribution of the 31 new SKUs launched in FY2025 and compare the gross margin to legacy products by end of Q1 2026.

Aurora Cannabis Inc. (ACB) - Ansoff Matrix: Diversification

Diversification, the most aggressive quadrant of the Ansoff Matrix, involves introducing new products into new markets. For Aurora Cannabis Inc., this strategy is centered on leveraging its non-cannabis assets, particularly the Bevo plant propagation business, and establishing a non-plant-touching foothold in the lucrative US market, all while monetizing its pharmaceutical-grade expertise.

The core objective here is to build stable, high-margin revenue streams independent of the federally regulated cannabis market, providing a crucial hedge against regulatory risk and market volatility. This is a defintely necessary move to sustain the record annual adjusted EBITDA of $49.7 million achieved in fiscal year 2025.

Expand the Bevo plant propagation business's (non-cannabis) product portfolio beyond vegetables and flowers to high-value specialty crops.

Aurora Cannabis Inc. can immediately increase the profitability of its Bevo business by shifting the product mix toward niche, high-value specialty crops. The Bevo segment already contributed $13.8 million in net revenue in Q4 2025, a 32% year-over-year increase, primarily from vegetable seedlings like tomatoes, cucumbers, and peppers.

Moving beyond these commodity crops and into specialty agriculture leverages Bevo's existing, advanced greenhouse infrastructure and propagation technology without significant new capital expenditure. This is a pure margin play.

• Target high-value crops like saffron crocus bulbs, which can yield over $5,000 per pound of spice.
• Propagate niche medicinal herbs (e.g., high-concentration botanicals) for the nutraceutical industry.
• Develop premium, grafted berry stock (e.g., specialty blueberry or raspberry varieties) for controlled environment agriculture (CEA) growers.

Acquire a US-based hemp-derived cannabidiol (CBD) wellness brand to gain a non-plant-touching foothold in the US market.

A strategic acquisition of a well-established, non-plant-touching US CBD wellness brand offers Aurora Cannabis Inc. immediate access to the US consumer without violating federal cannabis prohibition. This strategy is an essential pre-positioning move for future federal legalization.

The US CBD market is fragmented but massive. Aurora Cannabis Inc. can use its strong balance sheet, which held approximately $185.3 million in cash at the end of fiscal year 2025, to acquire a brand with a proven distribution network. This would bypass the capital-intensive process of building a brand from scratch and allow them to scale up their existing non-cannabis US sales, which already saw nearly $3.3 million in plant propagation sales in Q3 2025.

Leverage Bevo's agricultural technology to offer consulting or ancillary services to non-cannabis greenhouse operators, a segment that contributed $13.8 million in Q4 2025.

The Bevo business is not just a plant propagator; it is a technology and process leader in controlled environment agriculture (CEA). The $13.8 million in Q4 2025 revenue from Bevo demonstrates the commercial viability of its systems. This expertise-covering everything from automated seeding and grafting to integrated pest management (IPM) and climate control-can be packaged as a high-margin consulting service to other large-scale greenhouse operators globally.

Here's the quick math: if a consulting division could capture just 5% of the Q4 2025 Bevo revenue base in its first year as pure service revenue, that's an immediate $690,000 in high-margin, non-cannabis ancillary services. This revenue stream is predictable and not subject to the same regulatory hurdles as cannabis sales.

Enter the pet wellness market with CBD-infused products, utilizing the company's existing pharmaceutical-grade production standards.

Aurora Cannabis Inc.'s established reputation as a global leader in pharmaceutical-grade medical cannabis, backed by its European Union Good Manufacturing Practice (EU GMP) certification, is a massive competitive advantage.

The pet wellness market is booming, and consumers are willing to pay a premium for products they trust. Launching a line of CBD-infused pet products-like oils, treats, and topicals-under a separate, non-cannabis brand allows the company to capitalize on this trend immediately. The pharmaceutical-grade standard reduces the risk of product recalls and builds trust with veterinarians and consumers, justifying a 20-30% premium over non-certified competitors.

Form a strategic partnership with a pharmaceutical company to co-develop cannabinoid-based drugs (pharmaceutical drug development) for new therapeutic areas.

The highest-risk, highest-reward diversification is pharmaceutical drug development. Aurora Cannabis Inc. already has a commercial collaboration with Cogent International Manufacturing Ltd., a subsidiary of Vectura Fertin Pharma, Inc., to launch a CBD lozenge in late 2024. This existing relationship is the blueprint.

The next step is to formalize a co-development agreement for novel cannabinoid formulations targeting specific, high-value therapeutic areas. This shifts the focus from selling plant material to selling intellectual property (IP) and approved drugs, commanding significantly higher margins.

• Target therapeutic areas like refractory epilepsy, chronic pain, or anxiety disorders where existing data shows promise.
• The partnership should involve co-funding Phase 1 and Phase 2 clinical trials, which can cost between $20 million and $50 million per compound.
• Success here means securing a New Drug Application (NDA) and unlocking a global pharmaceutical market potentially worth billions, far exceeding the current annual medical cannabis net revenue of $244.4 million for fiscal year 2025.

Finance: draft a 13-week cash view by Friday to model the initial investment required for the US CBD brand acquisition and the first phase of a pharmaceutical co-development agreement.